Reading AVTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AVTX free→Reading AVTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AVTX free→QuarterlyIQ Insights · AVTX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 12, 2026 (the “Effective Date”), the Company entered into amendments to employment agreements with Garry A. Neil, M.D., the Company’s Chief Executive Officer, Christopher Sullivan, the Company’s Chief Financial Officer, Mittie Doyle, M.D., FACR, the Company’s Chief Medical Officer and Taylor Boyd, Chief Business Officer (together, the “Empl…
Unregistered Sales of Equity Securities. On June 11, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with an accredited investor to exchange 4,294.675 outstanding shares of the Company’s outstanding Series C non-voting convertible preferred stock, $0.001 par value per share (the “Series C Preferred Stock”) for 4,294.675 shares of the Company’s newly created Series C-1 non-voting convertible preferred stock, $0.001 par value per shar…
Material Modification to rights of Security Holders. To the extent required by
The filing pertains to equity plan amendments, not a management change.
Results of Operations and Financial Condition. On May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished hereto as Exhibit 99.1. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor sh…
of this Current Report on Form 8-K is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements…
Entry into a Material Definitive Agreement On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“C…
Results of Operations and Financial Condition. In connection with the Offering, the Company filed the Prospectus Supplement with the SEC, which contains certain information regarding the Company’s results of operations or financial condition for the quarter ended March 31, 2026, as set forth below. As of March 31, 2026, the Company estimates that it had cash, cash equivalents and short-term investments of approximately $82.0 million. This financial data as of March 31, 2026 is preliminary and…
Entry into a Material Definitive Agreement. On April 26, 2026 (the “ Effective Date ”), Avalo Therapeutics, Inc. (the “ Company ”) entered into a Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization (the “ Milestone Buyout and Amendment Agreement ”). As previously disclosed, the Company, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, AlmataBio, Inc. (“ AlmataBio ”) and Patrick J. Crutcher, solely in his capacity as the rep…
Departure of Directors or Certain Officers; Election of Directors. On March 23, 2026, Dr. Jonathan Goldman and Mitchell Chan, members of the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”), each notified the Company of his decision to not stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”). Dr. Goldman and Mr. Chan will each continue to serve as a member of the Board until the 2026 Annual Meetin…
Results of Operations and Financial Condition. On March 23, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is furnished hereto as Exhibit 99.1. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor…
of this Current Report on Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025 and its results of operations for the year ended December 31, 2025. The Company’s actual results for the year ended December 31, 2025 will be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and may differ materially from the above estimate. The information conta…
Results of Operations and Financial Condition. On November 6, 2025, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2025, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. Taylor Boyd - Chief Business Officer Mr. Boyd, 37 years old, has nearly 15 years of experience across biotech business development, corporate finance, and investment banking. Most recently, he s…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Appointment On September 16, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Kevin Lind to the Board, effective October 1, 2025. Mr. Lind will serve as a director until the Company’s 2026 Annual Meeting of Stockholders or until his successor is duly elected and qualified. Mr. Lind will s…
Results of Operations and Financial Condition. On August 7, 2025, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subjec…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 17, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Rita Jain, M.D. to the Board, effective immediately. Dr. Jain will serve as a director until the Company’s 2026 Annual Meeting of Stockholders or until her successor is duly elected and qualified. There are no arrangements or understandi…
Termination of a Material Definitive Agreement. As previously disclosed in May 2023, the Company entered into a Sales Agreement with Oppenheimer & Co. Inc. (“Oppenheimer”) as sales agent, which the Company and Oppenheimer amended in August 2023 (as amended, the “Initial Agreement”), pursuant to which the Company was permitted to offer and sell, from time to time through Oppenheimer, shares of the Company’s common stock having an aggregate offering price of up to $50.0 million. On June 3, 2025…
Entry into a Material Definitive Agreement. On June 5, 2025, Avalo Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as sales agent, pursuant to which the Company may offer and sell, from time to time through TD Cowen, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $75.0 million (the “Offering”). The issuance and sale of shares in the Offering, if any, by…
Results of Operations and Financial Condition. On May 12, 2025, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately. Mr. Heffernan is also being appointed Chairman of the Board. Mr. Heffernan will serve as a director until the Company’s 2025 Annual Meeting of Stockholders or until his successor is…
Results of Operations and Financial Condition. On March 20, 2025, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference. Information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.